Neurocrine Biosciences Inc (NBIX)
Return on total capital
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 570,500 | 336,700 | 221,000 | 127,200 | 139,500 |
| Long-term debt | US$ in thousands | — | — | 0 | 335,100 | 317,900 |
| Total stockholders’ equity | US$ in thousands | 2,589,700 | 2,232,000 | 1,707,800 | 1,374,000 | 1,126,200 |
| Return on total capital | 22.03% | 15.09% | 12.94% | 7.44% | 9.66% |
December 31, 2024 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $570,500K ÷ ($—K + $2,589,700K)
= 22.03%
The return on total capital for Neurocrine Biosciences Inc has shown a fluctuating trend over the years, starting at 9.66% on December 31, 2020, decreasing to 7.44% by December 31, 2021, then exhibiting a notable increase to 12.94% by December 31, 2022. The trend continued upwards with further growth to 15.09% by December 31, 2023, and significant improvement to 22.03% by December 31, 2024. This indicates that the company has been effectively utilizing its total capital to generate returns for its investors more efficiently in recent years, potentially reflecting successful strategic decisions and operational performance.
Peer comparison
Dec 31, 2024